These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 9526958)
21. Antiphospholipid antibodies and recurrent pregnancy loss: correlation between the activated partial thromboplastin time and antibodies against phosphatidylserine and cardiolipin. Rote NS; Dostal-Johnson D; Branch DW Am J Obstet Gynecol; 1990 Aug; 163(2):575-84. PubMed ID: 2117391 [TBL] [Abstract][Full Text] [Related]
22. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*. Liveris A; Bello RA; Friedmann P; Duffy MA; Manwani D; Killinger JS; Rodriquez D; Weinstein S Pediatr Crit Care Med; 2014 Feb; 15(2):e72-9. PubMed ID: 24335992 [TBL] [Abstract][Full Text] [Related]
23. Transient antiphospholipid antibodies associated with acute infections in children: a report of three cases and a review of the literature. Mizumoto H; Maihara T; Hiejima E; Shiota M; Hata A; Seto S; Atsumi T; Koike T; Hata D Eur J Pediatr; 2006 Jul; 165(7):484-8. PubMed ID: 16552544 [TBL] [Abstract][Full Text] [Related]
25. Transient lupus anticoagulant: an unusual cause of bruising in children. Anderson AK; Mohan U; Liesner R Emerg Med J; 2003 Sep; 20(5):E6. PubMed ID: 12954711 [TBL] [Abstract][Full Text] [Related]
26. Lupus anticoagulant testing: effect of the platelet count on the activated partial thromboplastin time. Brien WF; Schaus MR; Cooper KE; O'Keefe BT; Inwood M Br J Biomed Sci; 1993 Jun; 50(2):114-6. PubMed ID: 8219916 [TBL] [Abstract][Full Text] [Related]
27. A ROTEM method using APTT reagent and tissue factor as the clotting activators may better define bleeding heterogeneity in moderate or severe haemophilia A (part I: Study in plasma samples). He S; Eelde A; Petrini P; Wallen H; Gabrielsson L; Svensson J; Blombäck M; Holmström M Thromb Res; 2018 Nov; 171():7-13. PubMed ID: 30216822 [TBL] [Abstract][Full Text] [Related]
29. [Effect of composition of reagents for activated partial thromboplastin time on their sensitivity during analysis of blood coagulation factors]. Berkovskiĭ AL; Vasil'ev SA; Sergeeva EV; Kozlov AA Klin Lab Diagn; 2000 Apr; (4):34-8. PubMed ID: 10878941 [TBL] [Abstract][Full Text] [Related]
30. Frequency of specific coagulation inhibitors and antiphospholipid antibodies in Tunisian haemophiliacs. Kraiem I; Hadhri S; El Omri H; Sassi R; Chaabani W; Ennabli S; Skouri H Ann Biol Clin (Paris); 2012; 70(6):659-65. PubMed ID: 23207810 [TBL] [Abstract][Full Text] [Related]
31. The presence of antiphospholipid antibodies in healthy Bernese Mountain Dogs. Nielsen LN; Wiinberg B; Kjelgaard-Hansen M; Kristensen AT J Vet Intern Med; 2011; 25(6):1258-63. PubMed ID: 22092614 [TBL] [Abstract][Full Text] [Related]
32. Automated amidolytic method for evaluating the activated partial thromboplastin time compared with a conventional coagulation method. Tripodi A; Poggio M; Scapellato L; Mannucci PM Haemostasis; 1989; 19(4):205-12. PubMed ID: 2509308 [TBL] [Abstract][Full Text] [Related]
33. Screening for lupus anticoagulant: improving the performance of the lupus-sensitive PTT-LA. Luginbühl R; Barizzi G; Sulzer I; Lämmle B; Alberio L Int J Lab Hematol; 2011 Apr; 33(2):168-75. PubMed ID: 20860735 [TBL] [Abstract][Full Text] [Related]
34. [Activated partial thromboplastin time. Evaluation of sensitivity and validity for determination of factor VIII coagulant activity]. Camici M; Evangelisti L Minerva Med; 1993 Feb; 84(1-2):11-6. PubMed ID: 8464562 [TBL] [Abstract][Full Text] [Related]
35. An Easy Method to Eliminate the Effect of Lupus Anticoagulants in the Coagulation Factor Assay. Tang N; Yin S Clin Lab; 2016 Jul; 62(7):1363-1365. PubMed ID: 28164630 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of four coagulation tests to detect plasma lupus anticoagulants. Saxena R; Saraya AK; Kotte VK; Singh YN; Prasad L; Malviya AN Am J Clin Pathol; 1991 Dec; 96(6):755-8. PubMed ID: 1746492 [TBL] [Abstract][Full Text] [Related]
37. Elevated activated partial thromboplastin time during administration of first-generation adenoviral vectors for gene therapy for prostate cancer: identification of lupus anticoagulants. Malaeb BS; Gardner TA; Margulis V; Yang L; Gillenwater JY; Chung LW; Macik G; Koeneman KS Urology; 2005 Oct; 66(4):830-4. PubMed ID: 16230147 [TBL] [Abstract][Full Text] [Related]
38. As compared to kaolin clotting time, silica clotting time is a specific and sensitive automated method for detecting lupus anticoagulant. Dragoni F; Minotti C; Palumbo G; Faillace F; Redi R; Bongarzoni V; Avvisati G Thromb Res; 2001 Jan; 101(2):45-51. PubMed ID: 11342205 [TBL] [Abstract][Full Text] [Related]
39. Laboratory identification of lupus anticoagulants using the combination of activated partial thromboplastin time and Russell's viper venom at two phospholipid concentrations. Akkawat B; Chantarangkul V; Rojnuckarin P; Juntiang J J Med Assoc Thai; 2003 Jun; 86 Suppl 2():S451-8. PubMed ID: 12930024 [TBL] [Abstract][Full Text] [Related]
40. Non-parallelism in the one-stage coagulation factor assay is a phenomenon of lupus anticoagulants and not of individual factor inhibitors. Ruinemans-Koerts J; Peterse-Stienissen I; Verbruggen B Thromb Haemost; 2010 Nov; 104(5):1080-2. PubMed ID: 20806127 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]